source
- Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease drug into Phase 3Sling Therapeutics announced a $123 million Series C financing round aimed at moving its oral therapy for thyroid eye disease into a late‑stage trial and eventual market launch. The company has be…
- Medicare expands ACCESS pilot to cover more chronic conditions with outcome-based paymentsMedicare's ACCESS model, a pilot that pays technology providers for managing chronic diseases, is being broadened. Initially covering diabetes, hypertension, chronic musculoskeletal pain, depressi…